PALO ALTO, Calif., September 30, 2021 (GLOBE NEWSWIRE) – 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of new drugs that address unmet needs in inflammatory diseases, fibrosis and pain, announced today that it has received a Notice of Clearance, from the United States Patent and Trade Office, for application 16/661,769 “Postoperative Reduction Method Cognitive Dysfunction (DCPO) ) “

Each year, 300,000 older people suffer a hip fracture in the United States, with a similar estimated number in Europe and 1.3 million worldwide. About 25% of these patients develop a major complication, delirium; they become confused and lose awareness of themselves and their surroundings. This is very serious – patients with delirium are twice as likely to die and are four times more likely to require admission to a nursing home, and a significant number suffer from long-term loss of function. cognitive or post-operative or post-operative delirium. -Operative Cognitive Dysfunction (DCOP).

Currently, there is no approved treatment to prevent the development of delirium / POCD. Professor Marc Feldmann and Professor Jagdeep Nanchahal, co-founders of 180 Life Sciences, and their colleagues found in a preclinical model that inflammatory mediators released at the time of surgery to repair a fractured bone were associated with memory loss in animals. The administration of anti-TNF before surgery improved the results.

180 Life Sciences has granted an exclusive intellectual property license on this important discovery and patents have now been issued in the US and UK / EU, with initial coverage until 2031. Scientific findings suggest that the Administration of an anti-TNF antibody before surgery to block the effect of inflammatory mediators may reduce, or prevent, the development of delirium in this large and important group of elderly patients. These critical findings form the basis of a randomized controlled clinical trial planned by 180 Life Sciences and the University of Oxford team for elderly patients undergoing hip fracture surgery in the UK.

180 Life Sciences is an applicant and licensee of a large and growing patent portfolio for three major pharmaceutical platforms in the areas of inflammation, fibrosis and pain. The patent portfolio covers 16 patent families with 42 issued and 32 pending patents in several major jurisdictions including the US, Canada, UK / Europe, Australia, Japan and China.

The Company’s patent portfolio consists of three main sets of IP, which correspond to the respective program.

* The expiration of the EU patent to be granted must be indicated on the date of grant

The Company’s patent portfolio consists of both its own intellectual property and exclusive global licenses, with Oxford University Innovation Limited, the Kennedy Trust for Rheumatology Research, the University of Oxford, Stanford University and the ‘Hebrew University.

“The issuance of these additional patent assets further strengthens the intellectual property portfolio governing and protecting our programs,” said Dr James Woody, CEO of 180 Life Sciences, who continued, “We are committed to expanding our global heritage. of patents while continuing to develop. our internal pipeline and increase patient access to innovative therapies.

Approximately 180 Life Sciences Corp.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that address unmet needs in inflammatory disease, fibrosis and pain by leveraging the combined expertise of leading therapeutic authorities at the University of Oxford , Hebrew University and Stanford University. 180 Life Sciences is leading research to solve one of the world’s leading disease drivers: inflammation. The Company is conducting groundbreaking studies in clinical programs, which seek to develop new drugs to treat distinct areas of inflammation for which there are no effective therapies. The Company’s main platform is a new program for the treatment of fibrosis using anti-TNF (tumor necrosis factor).

Forward-looking statements

This press release contains “forward-looking statements”, including information about the views of management on the Company’s future expectations, plans and prospects, in connection with the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect”, “estimate”, “project”, “budget”, “plan”, “anticipate”, “intend”, “plan”, “power”, “power” , “Could”, “should,” “believes”, “predicted”, “potential”, “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results and, therefore, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements relating to expectations regarding the capitalization, resources and financing of the Company; expectations regarding future performance, growth and planned acquisitions; the Company’s continued listing on the NASDAQ Stock Exchange; the Company’s ability to execute its plans for the development and commercialization of new drugs and the timing and costs of these development programs; estimates of the size of markets for its potential drug products; a potential dispute involving the Company or the validity or enforceability of the Company’s intellectual property; global economic conditions; geopolitical events and regulatory developments; expectations, development plans and expected timelines for the Company’s drug candidates, pipeline and programs, including collaborations with third parties; access to additional funding and the potential absence of such funding; and the Company’s ability to raise funds in the future and the terms of such financing. These and other risk factors are included from time to time in the documents the Company files with the Securities and Exchange Commission, including, but not limited to its Forms 10-K, 10-Q and 8 -K, as well as in the proxy circular / final prospectus that the Company has filed in connection with the recent merger. These reports and documents are available at www.sec.gov. All subsequent written and oral forward-looking statements regarding the Company or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of their publication, including any forward-looking statements included in this press release, which are made only as of the date hereof. . The Company cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or commitment to publicly issue updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in the events, conditions or circumstances upon which such statement is made. is based, except in cases where otherwise provided by law.

Investors:

Jason Assad Director of IR 180 Life Sciences Corp (678) 570-6791 [email protected]

Media Relations:

Russo Partners David Schull [email protected] (212) 845-4271

AT&T to demand vaccines for 90,000 of its unionized workers

Copyright 2021 GlobeNewswire, Inc.


Source link

About The Author

Mark Lewis

Related Posts

Leave a Reply

Your email address will not be published.